Dimerix Ltd has released a press release.
CLARITY 2.0 COVID-19 Study Concludes Recruitment
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- New Patent Family Application for DMX-700
- DMX-700 Study Shows Significant 80% Reduction in Lung Injury
- REMAP-CAP COVID-19 Study Analysis Update
- New Clinical Trial for DMX-200 in Diabetic Kidney Disease
- Phase 3 FSGS Kidney Trial First Patient Recruited
Later from Dimerix
- Appendix 4E and 2022 Annual Report
- Dimerix Receives A$6.0M R&D Tax Incentive Rebate
- Chair address and CEO presentation to AGM
- CLARITY 2.0 COVID-19 Study Outcome
- DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix